Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MAPK14_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAPK14_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAPK14_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAPK14_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAPK14_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAPK14_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
GO:003133010 | Cervix | CC | negative regulation of cellular catabolic process | 63/2311 | 262/18723 | 1.10e-07 | 5.68e-06 | 63 |
GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
GO:000226210 | Cervix | CC | myeloid cell homeostasis | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
GO:00075689 | Cervix | CC | aging | 75/2311 | 339/18723 | 2.75e-07 | 1.13e-05 | 75 |
GO:00018908 | Cervix | CC | placenta development | 40/2311 | 144/18723 | 4.59e-07 | 1.77e-05 | 40 |
GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0421871 | Oral cavity | NEOLP | Cellular senescence | 43/1112 | 156/8465 | 1.05e-06 | 1.19e-05 | 7.49e-06 | 43 |
hsa0407171 | Oral cavity | NEOLP | Sphingolipid signaling pathway | 36/1112 | 121/8465 | 1.11e-06 | 1.21e-05 | 7.64e-06 | 36 |
hsa0516971 | Oral cavity | NEOLP | Epstein-Barr virus infection | 51/1112 | 202/8465 | 1.96e-06 | 2.01e-05 | 1.27e-05 | 51 |
hsa0516371 | Oral cavity | NEOLP | Human cytomegalovirus infection | 55/1112 | 225/8465 | 2.32e-06 | 2.30e-05 | 1.45e-05 | 55 |
hsa0471472 | Oral cavity | NEOLP | Thermogenesis | 56/1112 | 232/8465 | 2.86e-06 | 2.75e-05 | 1.73e-05 | 56 |
hsa046257 | Oral cavity | NEOLP | C-type lectin receptor signaling pathway | 30/1112 | 104/8465 | 1.69e-05 | 1.45e-04 | 9.12e-05 | 30 |
hsa0517071 | Oral cavity | NEOLP | Human immunodeficiency virus 1 infection | 49/1112 | 212/8465 | 4.05e-05 | 3.22e-04 | 2.02e-04 | 49 |
hsa0467056 | Oral cavity | NEOLP | Leukocyte transendothelial migration | 31/1112 | 114/8465 | 4.39e-05 | 3.41e-04 | 2.14e-04 | 31 |
hsa0472271 | Oral cavity | NEOLP | Neurotrophin signaling pathway | 31/1112 | 119/8465 | 1.06e-04 | 7.67e-04 | 4.82e-04 | 31 |
hsa0541773 | Oral cavity | NEOLP | Lipid and atherosclerosis | 47/1112 | 215/8465 | 2.39e-04 | 1.61e-03 | 1.01e-03 | 47 |
hsa0513571 | Oral cavity | NEOLP | Yersinia infection | 33/1112 | 137/8465 | 3.20e-04 | 2.00e-03 | 1.26e-03 | 33 |
hsa043805 | Oral cavity | NEOLP | Osteoclast differentiation | 31/1112 | 128/8465 | 4.35e-04 | 2.60e-03 | 1.63e-03 | 31 |
hsa051617 | Oral cavity | NEOLP | Hepatitis B | 37/1112 | 162/8465 | 4.41e-04 | 2.60e-03 | 1.63e-03 | 37 |
hsa041145 | Oral cavity | NEOLP | Oocyte meiosis | 31/1112 | 131/8465 | 6.64e-04 | 3.52e-03 | 2.21e-03 | 31 |
hsa046605 | Oral cavity | NEOLP | T cell receptor signaling pathway | 26/1112 | 104/8465 | 7.37e-04 | 3.72e-03 | 2.34e-03 | 26 |
hsa0401051 | Oral cavity | NEOLP | MAPK signaling pathway | 59/1112 | 302/8465 | 9.40e-04 | 4.67e-03 | 2.94e-03 | 59 |
hsa043705 | Oral cavity | NEOLP | VEGF signaling pathway | 17/1112 | 59/8465 | 1.12e-03 | 5.42e-03 | 3.41e-03 | 17 |
hsa0466871 | Oral cavity | NEOLP | TNF signaling pathway | 27/1112 | 114/8465 | 1.42e-03 | 6.55e-03 | 4.12e-03 | 27 |
hsa0472831 | Oral cavity | NEOLP | Dopaminergic synapse | 30/1112 | 132/8465 | 1.61e-03 | 7.30e-03 | 4.59e-03 | 30 |
hsa046217 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | SORAFENIB | SORAFENIB | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL585902 | AMG-548 | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3544930 | SC-80036 | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GEFITINIB | GEFITINIB | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | RHAMNETIN | RHAMNETIN | 24397781 |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | OPHIOBOLIN O | OPHIOBOLIN O | 22130129 |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL2107779 | SEMAPIMOD | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565642 | RALIMETINIB | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL1766582 | R-1487 | |
1432 | MAPK14 | TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | OSI-632 | OSI-632 | |